Biotechnologies Assets S.A. EBIT

The latest EBIT for BST.MC is $-3.8M as of December 2025. That compares with $1M in the prior-year period — down 474.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Biotechnologies Assets S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BST.MC's EBIT moved from $1M to $-3.8M — a 474.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biotechnologies Assets S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, BST.MC currently prints $-3.8M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Biotechnologies Assets S.A.'s growth, margins, and balance sheet.

A EBIT figure of $-3.8M for BST.MC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting BST.MC's EBIT ($-3.8M), review year-over-year change from $1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.